Click to copy
Click to copy

Alnylam: 2Q Earnings Snapshot

August 6, 2019

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Tuesday reported a loss of $219.5 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.02 per share. Losses, adjusted for one-time gains and costs, were $1.83 per share.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.81 per share.

The RNA interference drug developer posted revenue of $44.7 million in the period, also falling short of Street forecasts. Five analysts surveyed by Zacks expected $47.3 million.

Alnylam shares have declined 2% since the beginning of the year. The stock has dropped 22% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

All contents © copyright 2019 The Associated Press. All rights reserved.